Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. - Wikidata - wikimedia - TriplyDB

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

http://www.wikidata.org/entity/Q34999728

about

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease Effects of aclidinium on determinants of COPD severity: symptoms and quality of life Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?Muscarinic antagonists in early stage clinical development for the treatment of asthma.Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.Pharmacotherapies for COPD.An update on the efficacy and safety of aclidinium bromide in patients with COPD.Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease.Emerging drugs for chronic obstructive pulmonary disease.Future of chronic obstructive pulmonary disease management.The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.Emerging role of long acting muscarinic antagonists for asthma Symptom variability in COPD: a narrative review.Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.Drug-target residence time--a case for G protein-coupled receptors.Clinical use of aclidinium in patients with COPD.The role of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium.Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.Emerging Therapeutic Options for the Management of COPD.Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Aclidinium inhibits human lung fibroblast to myofibroblast transition.Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists.Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.

P2860

Q22306019-AAFDE4C7-5AE7-4884-A2AF-404464ABB7C2 Q27012625-1BE3E8ED-79B2-419F-9314-8199CB89A8AD Q27022636-925AB7FB-4F25-4181-8A10-089958CEA0AD Q27023223-8179FD1B-D6C7-4A90-91F8-129CC8863F48 Q28069533-36FAE33C-83EA-4878-B1DF-E273F0243F36 Q30365242-2D0FBD99-B80A-4B1E-B1DC-C75CAB1AB8DC Q30396144-9A66223D-7A96-4E32-A233-A88342CEA91C Q34336907-2D6D3970-5D94-419A-B6BB-D317D3086008 Q34903093-B68DD0C1-B2EF-4F2D-887B-8E96AEFBB52C Q34995066-17E09634-6F23-4C76-BC4E-259388A35330 Q35268320-EC07FA56-D3CD-466A-B6D7-BE7833E4FF48 Q35914818-E259ED71-B343-4207-9760-DED28A7B24E2 Q36843717-1BC33811-CEA2-4178-8208-789CEF42B7E0 Q37795391-6958DB3B-111D-4A18-A5B5-8896CB8F581E Q37894102-A293285E-0B7F-4D3F-8C31-CF6F92889FC4 Q37937554-3D1B7B40-0676-4786-B375-D2C932E894A6 Q37984088-D7D52F2B-35BC-4710-A0B1-6C51D59CFEB0 Q38025725-2C4A2ACF-04CA-4D9A-86D0-6114D28E15A6 Q38052955-68A0BA0F-0E65-412F-8FE8-EA55C65A1D01 Q38066977-F612629C-7D02-4841-B91E-0520B9DDC3EA Q38093655-C895F2D0-B93A-4B24-A822-D71BDCC69E26 Q38107935-6BB89389-9736-47CD-AAB5-B4B6BF38EF9A Q38112092-ADAA88F2-19EA-4015-806C-42D10AFBFCB6 Q38189272-225B676D-5DBF-42CA-8289-3485E6C92EA3 Q38210538-A9780403-37BF-4F85-A763-A051177B53DE Q38287153-9A684631-F14C-43D0-9B69-9172A969ABAA Q38344780-BAB5C52A-8A3C-4307-83E3-4AE740461C83 Q38371305-F9B96759-7BE2-4E24-A761-2C82EB623DB3 Q38432438-59C3D324-19E6-4CF4-B769-00F751B0AADE Q38586322-9E823E2B-41ED-4044-8E14-2B63648A8993 Q38592062-A6E1E17D-FC29-4324-AAD9-9CFD7E4FAF11 Q38604650-DBBEAE89-4823-4108-A6E2-134C2E3446DD Q38783067-C9EF50FA-DEF1-4572-A00F-52FFFD0DD746 Q39936577-F61010B8-EE50-4F16-B30A-DE9D4DC0E3FB Q40090191-17CAD2A3-53E2-4893-90B2-76CD52151C20 Q41252525-10CCA1C0-3C42-451A-AAB1-F264B31A043D Q43997723-C90B969F-9CA3-414B-B582-96C3FAA95F82 Q45560084-10AACA27-B94F-4792-A18D-391EF4112867 Q48030937-056BE56D-0A83-4652-BC75-3704E4D146C0 Q55284121-59DA1C2A-159A-4683-9EB9-8A1ED1F496F2

P2860

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

http://www.wikidata.org/entity/Q34999728

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Characterization of aclidinium ...... rable pharmacological profile.

@ast

Characterization of aclidinium ...... rable pharmacological profile.

@en

Characterization of aclidinium ...... rable pharmacological profile.

@nl

type

label

Characterization of aclidinium ...... rable pharmacological profile.

@ast

Characterization of aclidinium ...... rable pharmacological profile.

@en

Characterization of aclidinium ...... rable pharmacological profile.

@nl

prefLabel

Characterization of aclidinium ...... rable pharmacological profile.

@ast

Characterization of aclidinium ...... rable pharmacological profile.

@en

Characterization of aclidinium ...... rable pharmacological profile.

@nl

P1433

Q34999728-5D0A2D4F-C0C7-4DA2-8C26-2FCA882E1422

P1476

Q34999728-28BFB4B7-AE67-4312-83F5-F3D0EBF8FC2A

P2093

Q34999728-1F5A8492-D2F8-4FA1-93CA-E6763A0A45CD

Q34999728-29B00ABA-5482-4944-BE6F-EA14F496AE89

Q34999728-378B83C1-FCB2-4405-85E2-E4DB0782D05C

Q34999728-5C6994F3-45B1-4639-B05B-08E99501417A

Q34999728-5ED5CA90-A428-43E3-AB62-3D20CD37B8C0

Q34999728-704DDA52-9868-4C10-8FF9-FBD6CC62C459

Q34999728-8C9EC32C-7717-4BCC-AAFF-550762A2293B

Q34999728-8FA22788-9B34-4824-902B-6B769C7AACA2

Q34999728-A0409EB7-36F0-43D4-ADE2-AB6D35879E96

Q34999728-B242FE09-1DFC-489C-8A44-47859544A804

P304

Q34999728-7C9613D5-0584-45FF-9230-FCBC444F923C

P31

Q34999728-A3D93EC9-EF27-4A96-9AB8-F1034A9AA4E7

P356

Q34999728-9AF6BAE8-B119-4D15-A0B9-4520DCAAC76C

P407

Q34999728-B7AD3EBF-2E3D-4C82-AF4C-5C870CBB7F25

P433

Q34999728-BA3A1A4F-9465-48AB-8DCE-1DB58B45D5F7

P478

Q34999728-E3FE9268-6FD8-4A33-BC36-D39B9C622C23

P50

Q34999728-68F45185-1776-40FD-BBDD-0E90AF6FB868

Q34999728-A299C2A2-8831-4433-AB27-01C05FD94BA0

P577

Q34999728-384C81E2-4155-4668-99B4-5430BB67C7C2

P5875

Q34999728-A27066E0-2553-4982-AF79-6E8FE567141C

P698

Q34999728-3477BC1C-C210-4DF2-8278-50F57871A28E

P921

Q34999728-27BBB9B1-D835-48B0-87B4-62720189FC84

Q34999728-8B7785DE-E727-403D-A31C-D1BC64288573

P356

JPET.109.151639

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Characterization of aclidinium ...... orable pharmacological profile

@en

P2093

Blanca Reyes

http://www.w3.org/2001/XMLSchema#string

Carla Carcasona

http://www.w3.org/2001/XMLSchema#string

Cristina Carreño

http://www.w3.org/2001/XMLSchema#string

Dolors Vilella

http://www.w3.org/2001/XMLSchema#string

Hamish Ryder

http://www.w3.org/2001/XMLSchema#string

Israel Ramos

http://www.w3.org/2001/XMLSchema#string

Jesús Llenas

http://www.w3.org/2001/XMLSchema#string

Jordi Gras

http://www.w3.org/2001/XMLSchema#string

Jorge Beleta

http://www.w3.org/2001/XMLSchema#string

Julio Cortijo

http://www.w3.org/2001/XMLSchema#string

P304

740-751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.109.151639

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

331

http://www.w3.org/2001/XMLSchema#string

P50

Amadeu Gavaldà

Esteban Morcillo

P577

2009-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26770352

http://www.w3.org/2001/XMLSchema#string

P698

19710368

http://www.w3.org/2001/XMLSchema#string

P921

aclidinium bromide